MA43404A - Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques - Google Patents

Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Info

Publication number
MA43404A
MA43404A MA043404A MA43404A MA43404A MA 43404 A MA43404 A MA 43404A MA 043404 A MA043404 A MA 043404A MA 43404 A MA43404 A MA 43404A MA 43404 A MA43404 A MA 43404A
Authority
MA
Morocco
Prior art keywords
expression
compositions
treatment
conditions
methods
Prior art date
Application number
MA043404A
Other languages
English (en)
Inventor
Amit N Patel
Dimki S Patel
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of MA43404A publication Critical patent/MA43404A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043404A 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques MA43404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254139P 2015-11-11 2015-11-11

Publications (1)

Publication Number Publication Date
MA43404A true MA43404A (fr) 2018-10-17

Family

ID=57543150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043404A MA43404A (fr) 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Country Status (14)

Country Link
US (3) US11154622B2 (fr)
EP (1) EP3387010A1 (fr)
JP (1) JP6976244B2 (fr)
KR (1) KR20180069081A (fr)
CN (1) CN108713025A (fr)
AU (1) AU2016353342B2 (fr)
BR (1) BR112018009645A2 (fr)
CA (1) CA3004742A1 (fr)
HK (1) HK1259137A1 (fr)
MA (1) MA43404A (fr)
MX (1) MX2018005886A (fr)
RU (1) RU2758489C2 (fr)
SG (1) SG11201803934YA (fr)
WO (1) WO2017083750A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132494A1 (fr) 2017-01-10 2018-07-19 Intrexon Corporation Modulation de l'expression de polypeptides par l'intermédiaire de nouveaux systèmes d'expression de commutateurs géniques
KR20190038419A (ko) * 2017-09-29 2019-04-08 (주)벳바젠 심부전의 예방 또는 치료용 약학적 조성물
EP3762010A4 (fr) 2018-03-06 2022-04-06 Precigen, Inc. Vaccins contre l'hépatite b et utilisations de ces derniers
WO2019218091A1 (fr) * 2018-05-18 2019-11-21 UNIVERSITé LAVAL Vecteurs pour l'immunisation par adn
US20210361755A1 (en) * 2018-05-25 2021-11-25 The Wistar Institute Tumor-specific neoantigens and methods of using the same
EP3860716A2 (fr) 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions et méthodes concernant des lymphocytes t gamma delta modifiés et non modifiés pour le traitement de tumeurs solides
EP3860645A1 (fr) 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions et procédés concernant des cellules t gamma delta génétiquement modifiées ou non modifiées pour le traitement de tumeurs hématologiques
EP3946505A1 (fr) * 2019-03-29 2022-02-09 Abiomed, Inc. Systèmes et procédés de déchargement ventriculaire gauche en thérapie biologique ou en thérapie génique vectorisée
CA3106735A1 (fr) * 2019-05-21 2020-11-26 Universite Laval Compositions immunogenes du virus de la fievre hemorragique de crimee-congo
EP4031672A1 (fr) * 2019-09-20 2022-07-27 UCL Business Ltd Composition de thérapie génique et traitement de la cardiomyopathie arrythmogénique ventriculaire droite
MX2023001615A (es) 2020-08-07 2023-03-08 Spacecraft Seven Llc Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav.
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2023019272A1 (fr) * 2021-08-12 2023-02-16 Temple University Of The Commonwealth System Of Higher Education Administration rétrograde veineuse ou sinusale coronaire d'agents thérapeutiques
WO2023232984A1 (fr) * 2022-06-02 2023-12-07 Patrick Most Protéine s100a1 destinée à être utilisée dans le traitement et la prévention d'une prolongation d'infarctus

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
MXPA02009157A (es) 2000-03-22 2004-04-05 Rohm & Haas Nuevo sistema de expresion genetica inducible a base del receptor de ecdisona.
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
EP1456346B1 (fr) 2001-02-20 2012-02-15 Intrexon Corporation Nouveau systeme d'expression genetique inductible base sur le recepteur d'ecdysone/recepteur de retinoide x invertebre
EP1373470B1 (fr) 2001-02-20 2013-04-24 Intrexon Corporation Nouveaux recepteurs de mutants de substitution et utilisation de ceux-ci dans un systeme d'expression genique inductible a base de recepteurs nucleaires
WO2002066615A2 (fr) 2001-02-20 2002-08-29 Rheogene, Inc. Nouveaux recepteurs a mutant de substitution et utilisation de ceux-ci dans un systeme d'expression de gene inductible fonde sur un recepteur nucleaire
MXPA03007492A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Receptores de retinoide x quimerico y su uso en un sistema de expresion de gen inducible basado en receptor de ecdisona novedoso.
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7919269B2 (en) 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7563879B2 (en) 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
PL2043662T3 (pl) 2006-07-26 2016-03-31 Intrexon Corp Sposoby i kompozycje do leczenia choroby
WO2008088870A1 (fr) 2007-01-19 2008-07-24 Progressive Gaming International Corporation Système d'identification de surveillance de table, étiquetage de pari et cartographie de coordonnées
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
AU2008307643B9 (en) * 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
HUE024479T2 (en) 2007-10-08 2016-01-28 Intrexon Corp Genetically altered dendritic cells and uses for cancer treatment
AU2009223115B2 (en) * 2008-03-14 2015-09-24 Humanzyme, Inc. Recombinant production of authentic human proteins using human cell expression systems
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
EP2473196B1 (fr) 2009-08-28 2017-05-31 The Cleveland Clinic Foundation Administration de sdf-1 en vue du traitement de tissus ischémiques
MX362513B (es) 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
JP6189754B2 (ja) 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
WO2014077825A1 (fr) * 2012-11-16 2014-05-22 United Biomedical, Inc. Vaccin d'urgence à base d'un peptide synthétique contre la fièvre aphteuse (fmd)
WO2014089121A2 (fr) * 2012-12-03 2014-06-12 Thomas Ichim Administration rétrograde de cellules et d'acides nucléiques pour le traitement de maladies cardiovasculaires
CN105377268A (zh) 2013-03-15 2016-03-02 克利夫兰临床医学基金会 用于治疗心肌梗塞的sdf-1的逆行递送
WO2016187585A1 (fr) 2015-05-20 2016-11-24 Viventia Bio Inc. Lieur désimmunisé et méthodes d'utilisation
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用

Also Published As

Publication number Publication date
WO2017083750A1 (fr) 2017-05-18
BR112018009645A2 (pt) 2018-11-13
HK1259137A1 (zh) 2019-11-29
US20180360992A1 (en) 2018-12-20
US11154622B2 (en) 2021-10-26
KR20180069081A (ko) 2018-06-22
RU2758489C2 (ru) 2021-10-28
RU2018117674A3 (fr) 2020-04-20
EP3387010A1 (fr) 2018-10-17
JP2018536405A (ja) 2018-12-13
US20220072159A1 (en) 2022-03-10
AU2016353342B2 (en) 2021-04-01
RU2018117674A (ru) 2019-12-13
SG11201803934YA (en) 2018-06-28
CA3004742A1 (fr) 2017-05-18
US20240148908A1 (en) 2024-05-09
AU2016353342A1 (en) 2018-05-24
CN108713025A (zh) 2018-10-26
MX2018005886A (es) 2018-08-15
JP6976244B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
MA43404A (fr) Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL264025A (en) Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
IL288375A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
WO2016057658A8 (fr) Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
FR3020951B1 (fr) Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique.
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
MA52579A (fr) Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases